

## Influenza B Detection Expected to Impact on Quarter Sales

**Genetic Signatures [ASX:GSS]** (“GSS” or “the Company), a global molecular diagnostics company, advises that it has received a report of inconsistencies in the detection of the influenza B virus when employing the *EasyScreen*<sup>™</sup> Respiratory Pathogen Detection Kit. The Company has undertaken an investigation and found that this season’s influenza B virus is not being consistently detected in a small proportion of low viral concentration samples. The Company is well-advanced in resolving this issue, which is specific to the influenza B virus. The detection of influenza A virus is unaffected.

Minor changes to the assay design have been shown to restore detection of low viral concentration influenza B-positive samples. Genetic Signatures has advised the regulatory authorities of the reported detection inconsistencies, and the Company’s ability to implement a solution in a relatively short timeframe. However, in the interim, the sale of Genetic Signatures *EasyScreen*<sup>™</sup> Respiratory Pathogen Detection Kit has been impacted during this current quarter. At this time, we expect forecast revenue to be approximately \$2 million for Q1 FY2023 with no expected impact in following quarterly revenue periods.

**John Melki, CEO and Managing Director of Genetic Signatures** said *“We remain very confident that we will address this in a timely manner and restore regular use of our EasyScreen<sup>™</sup> Respiratory Pathogen Detection Kit as the preferred molecular test for respiratory pathogens. However, as this has unfortunately occurred during the middle of the Australian ‘flu season, it is expected to have an impact on our revenues for the current quarter.”*

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**

**Chief Executive Officer**

[john.melki@geneticsignatures.com](mailto:john.melki@geneticsignatures.com)

T: +61 (0)2 9870 7580

**Karl Pechmann**

**Chief Financial Officer**

[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**<sup>®</sup>. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*<sup>™</sup> brand. Genetic Signatures’ proprietary MDx **3base**<sup>®</sup> platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*<sup>™</sup> respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base**<sup>®</sup> technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.